BioMedNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of Antiviral Drug Molecular Characterization Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing and formulation technology does not create a covalently bonded new molecular entity (“NME”). In addition, the study confirmed that each of the five drugs tested remained stable without undergoing any change in chemical structure. The five drugs included remdesivir, ebastine, bepridil, rupintrivir and colchicine. The company noted that these findings are strongly supportive of accelerated regulatory filings through the Food and Drug Administration (“FDA”) and other international regulators with the end goal of an accelerated market authorization process. The company anticipates pursuing collaboration opportunities with other pharmaceutical industry partners to incorporate its exclusive technology in other ways.

To view the full press release, visit https://ibn.fm/WQY3G

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork